ReviewAnnals of hematology2014
Progress in detecting cell-surface protein receptors: the erythropoietin receptor example.
Review in Annals of hematology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 47 citations in OpenAlex.
- An asymmetric tetrabody is a potent and efficacious agonist of the erythropoietin receptor in vitro and in vivo.Protein science : a publication of the Protein Society · 2025Article
- Fine-tuning the N-glycosylation of recombinant human erythropoietin using Chlamydomonas reinhardtii mutants.Plant biotechnology journal · 2024Article
- Synthesis, Biological Activity, ADME and Molecular Docking Studies of Novel Ursolic Acid Derivatives as Potent Anticancer Agents.International journal of molecular sciences · 2023Article
- Mesenchymal Stromal Cells: a Possible Reservoir for HIV-1?Stem cell reviews and reports · 2022Review
- Effect of fetal bovine serum on erythropoietin receptor expression and viability of breast cancer cells.Saudi journal of biological sciences · 2020Article
- FISIK: Framework for the Inference of In Situ Interaction Kinetics from Single-Molecule Imaging Data.Biophysical journal · 2019Article
- Folate Receptor α-TargetedMolecular pharmaceutics · 2019Article
- SteamedFrontiers in pharmacology · 2019Article
- The Discovery and Development of Liraglutide and Semaglutide.Frontiers in endocrinology · 2019 · on this mapReview
- Contradictory effects of erythropoietin on inhibitory synaptic transmission in left and right prelimbic cortex of mice.Neurobiology of stress · 2018Article
- Protective Role of Histidine Supplementation Against Oxidative Stress Damage in the Management of Anemia of Chronic Kidney Disease.Pharmaceuticals (Basel, Switzerland) · 2018Review
- Expansion of EPOR-negative macrophages besides erythroblasts by elevated EPOR signaling in erythrocytosis mouse models.Haematologica · 2018Article
- Expression of platelet-derived growth factor BB, erythropoietin and erythropoietin receptor in canine and feline osteosarcoma.Veterinary journal (London, England : 1997) · 2015Article
- [Erythropoiesis: Physiology, pathophysiology, and algorithm for classification of the type of anemia].Der Internist · 2015Article
- Review
- In-vivo detection of the erythropoietin receptor in tumours using positron emission tomography.European radiology · 2015Article
- Erythropoietin improves the accumulation and therapeutic effects of carboplatin by enhancing tumor vascularization and perfusion.Theranostics · 2015Article
- Osteoblasts: a novel source of erythropoietin.Current osteoporosis reports · 2014Review
- Erythropoietin increases macrophage-mediated T cell suppression.Cellular immunologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Testing for the presence of specific cell-surface receptors (such as EGFR or HER2) on tumor cells is an integral part of cancer care in terms of treatment decisions and prognosis. Understanding the strengths and limitations of these tests is important because inaccurate results may occur if procedures designed to prevent false-negative or false-positive outcomes are not employed. This review discusses tests commonly used to identify and characterize cell-surface receptors, such as the erythropoietin receptor (EpoR). First, a summary is provided on the biology of the Epo/EpoR system, describing how EpoR is expressed on erythrocytic progenitors and precursors in the bone marrow where it mediates red blood cell production in response to Epo. Second, studies are described that investigated whether erythropoiesis-stimulating agents could stimulate tumor progression in cancer patients and whether EpoR is expressed and functional on tumor cells or on endothelial cells. The methods used in these studies included immunohistochemistry, Northern blotting, Western blotting, and binding assays. This review summarizes the strengths and limitations of these methods. Critically analyzing data from tests for cell-surface receptors such as EpoR requires understanding the techniques utilized and demonstrating that results are consistent with current knowledge about receptor biology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.